Search for: "TEVA PHARMACEUTICAL INDUSTRIES LTD" Results 161 - 180 of 261
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 May 2010, 8:31 am
But again today, May 20, 2010 the firm has upgraded the stock from Hold to Buy.According to Benzinga’s Monica Gerson who writes that Standpoint analyst Ronnie Moas had also upgraded shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA), Dell Inc (NASDAQ: DELL), HP (NYSE: HPQ) and Xerox Corporation (NYSE: XRX), simultaneously, from “hold” to “buy. [read post]
17 Jan 2008, 10:00 pm
: (Against Monopoly),Structuring a decentralized world - Institute for Ethics and Emerging Technologies: The necessity of open biotechnology: (Patent Lens),A skeptical look at the Automated Content Access Protocol: (Ars Technica),5 practical things to incorporate in a corporate IP strategy: (IP ThinkTank), Legal models for online content enforcement: (OpenContentLawyer),Germany, Chinese copies and misdirected ‘strategy': (IP… [read post]
14 Jul 2020, 5:00 am by Carolyn Casey, J.D.
The makers named in the recall are Apotex Corp., Amneal Pharmaceuticals, Marksans Pharma Limited’s Time-Cap Labs, Inc., Lupin Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc. [read post]
30 Oct 2006, 5:58 am
District Court for the District of Columbia in Teva Pharmaceuticals v. [read post]
20 Sep 2011, 6:35 am by Bexis
Teva Pharmaceutical Industries Ltd., 2011 WL 4062219 (E.D. [read post]
2 Feb 2018, 1:31 pm by Gregory Sephton
Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., Case 2016-1284, 2016-1787 (Fed. [read post]
8 Dec 2007, 11:00 am
: (IP Think Tank), WIPO - Idris gets paid out to leave early: (IAM), (Patent Prospector), Deutsche Grammophon ditches DRM: (ArsTechnica)PharmaFDA revisits NCE exclusivity for enantiomers: (Arnall Golden & Gregory), Accupril (Quinapril) - Judge finds against Teva and holds Warner-Lambert patent enabled: (IPLaw360), (OrangeBookBlog), Altace / Tritace / Ramace (Ramipril) - King Pharmaceuticals loses CAFC rehearing bid:… [read post]
17 Nov 2010, 1:48 am by Kelly
(Patently-O) US: Amicus brief filed by Alnylam Pharmaceuticals argues that Funk Bros. is about obviousness, not patent eligibility: AMP v USPTO (Holman’s Biotech IP Blog) US: Amicus briefs in AMP v USPTO: Genetic Alliance (Patent Docs) US: Patent expirations will stabilise the pharmaceutical industry (BiotechBlog) US: Generic industry headed for a ‘180-day exclusivity cliff’ (FDA Law Blog) US: PTO clarifies PTE availability in post-PhotoCure and… [read post]
25 Jan 2017, 11:25 pm
However, claim 27 is to “a pharmaceutical composition comprising a compound according to any one of claims 1-25 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients” (emphasis added). [read post]
17 Oct 2008, 1:32 pm
Proposed EU information laws on prescription drugs (IPmed) Iceland: Supplementary Protection Certificates (SPCs) in Iceland (The SPC blog) India: Roche implements 'mass serialisation' anti-counterfeiting technology (Spicy IP) Indonesia: Patent application on oil palm hybrids (navigating the patent maze) United States: New PMCA research: State legislative proposals restricting access to generic medicines would increase cost $29 billion over 10 years (GenericsWeb) US:… [read post]
3 Aug 2020, 7:02 am by Elizabeth McAuliffe (Bristows)
Where there are specialists with a focus on the kind of work with which a patent is concerned, they are the relevant addressees of the patent and their specialist skills are attributed to the notional skilled person, even if the patent might also be of a broader application and of interest to non-specialists (Medimmune Ltd v Novartis Pharmaceuticals UK Ltd [2013] RPC 27). [read post]
16 May 2019, 9:30 am by Silver Law Group
Frost is a biotech billionaire who is CEO and chairman of Opko Health and former chairman of Teva Pharmaceutical Industries Ltd. [read post]
10 Aug 2010, 8:44 pm by Marie Louise
  General Coverage of anti-counterfeit policy debate varies widely across global media (IP Watch) WHO declares flu pandemic over; experts behind response to be revealed (IP Watch) Australia: TGA to implement alert system for new ARTG registrations (IP Whiteboard) EU: Final petition of the Advocate-General / Jodosulfuron- SPC for plant protection products (EPLAW) India: Parliamentary Committee on Health tables report on issues relating to availability of generic medicines (Spicy IP) Peru:… [read post]
23 Nov 2007, 9:00 am
You can separately subscribe to the IP Thinktank Global week in Review at []GlobalReputation and privacy in the online social media world: (IPWar's), McAfee typosquatting study results and implications: (IPWar's),Larry Lessig's comments on how creativity is being strangled by the law: (BLOG@IP::JUR)Two interesting papers on Creative Commons: (CreativeCommons)Friction and 'Warfighting': (IP Think Tank),More on the controversy at WIPO over Kamil Idris'… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]